Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 21 studies | 77% ± 14% | |
lung | 18 studies | 74% ± 13% | |
intestine | 12 studies | 69% ± 18% | |
brain | 11 studies | 45% ± 23% | |
kidney | 9 studies | 66% ± 22% | |
eye | 9 studies | 57% ± 23% | |
bone marrow | 7 studies | 60% ± 23% | |
lymph node | 6 studies | 84% ± 9% | |
pancreas | 5 studies | 74% ± 25% | |
uterus | 5 studies | 74% ± 23% | |
liver | 5 studies | 76% ± 17% | |
placenta | 4 studies | 82% ± 19% | |
prostate | 4 studies | 78% ± 24% | |
breast | 4 studies | 83% ± 5% | |
heart | 3 studies | 35% ± 12% | |
adipose | 3 studies | 46% ± 25% | |
adrenal gland | 3 studies | 71% ± 17% | |
esophagus | 3 studies | 72% ± 19% | |
skin | 3 studies | 69% ± 23% | |
thymus | 3 studies | 73% ± 28% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
adrenal gland | 100% | 30060.46 | 258 / 258 | 100% | 472.51 | 230 / 230 |
esophagus | 100% | 19649.99 | 1445 / 1445 | 100% | 266.84 | 183 / 183 |
kidney | 100% | 21278.15 | 89 / 89 | 100% | 255.42 | 901 / 901 |
liver | 100% | 13898.93 | 226 / 226 | 100% | 256.19 | 406 / 406 |
ovary | 100% | 15649.67 | 180 / 180 | 100% | 278.90 | 430 / 430 |
pancreas | 100% | 13418.78 | 328 / 328 | 100% | 349.69 | 178 / 178 |
stomach | 100% | 16932.68 | 359 / 359 | 100% | 320.41 | 286 / 286 |
uterus | 100% | 17143.86 | 170 / 170 | 100% | 429.62 | 459 / 459 |
skin | 100% | 23591.74 | 1808 / 1809 | 100% | 383.10 | 472 / 472 |
intestine | 100% | 21429.53 | 966 / 966 | 100% | 380.41 | 526 / 527 |
lung | 100% | 26624.82 | 577 / 578 | 100% | 354.48 | 1154 / 1155 |
brain | 100% | 21750.78 | 2634 / 2642 | 100% | 308.57 | 705 / 705 |
thymus | 100% | 18582.52 | 652 / 653 | 100% | 329.84 | 604 / 605 |
breast | 100% | 21708.43 | 459 / 459 | 100% | 344.59 | 1114 / 1118 |
bladder | 100% | 20535.52 | 21 / 21 | 100% | 406.41 | 502 / 504 |
prostate | 100% | 18334.20 | 245 / 245 | 100% | 339.46 | 500 / 502 |
adipose | 100% | 23744.54 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 241.48 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 816.31 | 29 / 29 |
muscle | 100% | 27015.94 | 803 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 100% | 71851.28 | 929 / 929 | 0% | 0 | 0 / 0 |
spleen | 100% | 37995.84 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 461.72 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 304.27 | 1 / 1 |
blood vessel | 100% | 21862.25 | 1333 / 1335 | 0% | 0 | 0 / 0 |
heart | 99% | 22182.20 | 855 / 861 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0045732 | Biological process | positive regulation of protein catabolic process |
GO_1902268 | Biological process | negative regulation of polyamine transmembrane transport |
GO_0090316 | Biological process | positive regulation of intracellular protein transport |
GO_0006596 | Biological process | polyamine biosynthetic process |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0005515 | Molecular function | protein binding |
GO_0008073 | Molecular function | ornithine decarboxylase inhibitor activity |
Gene name | OAZ1 |
Protein name | OAZ1 protein (Ornithine decarboxylase antizyme 1, isoform CRA_a) Ornithine decarboxylase antizyme 1 Ornithine decarboxylase antizyme 1 (AZ1) (ODC-Az) |
Synonyms | hCG_22710 OAZ |
Description | FUNCTION: Ornithine decarboxylase (ODC) antizyme protein that negatively regulates ODC activity and intracellular polyamine biosynthesis and uptake in response to increased intracellular polyamine levels. Binds to ODC monomers, inhibiting the assembly of the functional ODC homodimer, and targets the monomers for ubiquitin-independent proteolytic destruction by the 26S proteasome . Triggers ODC degradation by inducing the exposure of a cryptic proteasome-interacting surface of ODC . Stabilizes AZIN2 by interfering with its ubiquitination . Also inhibits cellular uptake of polyamines by inactivating the polyamine uptake transporter. SMAD1/OAZ1/PSMB4 complex mediates the degradation of the CREBBP/EP300 repressor SNIP1. Involved in the translocation of AZIN2 from ER-Golgi intermediate compartment (ERGIC) to the cytosol . . |
Accessions | J3QQY4 ENST00000582888.8 K7EPM6 K7ERW1 P54368 ENST00000602676.6 [P54368-1] ENST00000590943.6 ENST00000588673.3 Q2M222 |